Skip to main content
. 2023 May 10;13(2):218–236. doi: 10.3390/jox13020017

Figure 2.

Figure 2

Proportion of alanine aminotransferase (ALT) elevation observed in clinical or observational trials [21,32,33,34,35,36,37,38,39,40,41,42,43,45,47,48]. For each respective SARM, doses were considered low if they were in the 1st quartile, medium if in the 2–3rd quartile, and high if in the 4th quartile of doses across all included trials of the respective SARM.